Achieving glycemic goals with addition of incretin-based therapies to insulin in patients with type 2 diabetes mellitus

American Journal of the Medical Sciences

Volumn 347, Issue 6, 2014, Pages 491-501

  Tibaldi, Joseph ^a  

^a Queens Diabetes and Endocrinology   (United States)

Author keywords

Hypoglycemia; Incretin; Insulin; Type 2 diabetes mellitus; Weight

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; PRAMLINTIDE; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ADD ON THERAPY; CLINICAL TRIAL (TOPIC); CONSENSUS; EDEMA; GLUCAGON RELEASE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PEER REVIEW; REVIEW; WEIGHT GAIN;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GLYCEMIC INDEX; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN;

EID: 84901604517     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0000000000000202     Document Type: Review

References (45)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53
2. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35: 1364-79
4. Ranjit Unnikrishnan I, Anjana RM, Mohan V. Importance of controlling diabetes early - The concept of metabolic memory, legacy effect and the case for early insulinisation. J Assoc Physicians India 2011;59:8-12
5. Johnston SS, Conner C, Aagren M, et al. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care 2011;34:1164-70
6. Fox CS, Pencina MJ, Wilson PW, et al. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham Heart Study. Diabetes Care 2008;31: 1582-4
7. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on type 2 diabetes mellitus: An algorithm for glycemic control. Endocr Pract 2009;15:540-59
8. DeFronzo R. Banting lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95
9. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA (1c). Diabetes Care 2003;26:881-5
10. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract 2013;19:327-36
11. Triplitt C. How to initiate, titrate, and intensify insulin treatment in type 2 diabetes. US Pharm 2007;32:10-6
12. Hamaty M. Insulin treatment for type 2 diabetes: When to start, which to use. Cleve Clin J Med 2011;78:332-42
13. Vaag A, Lund SS. Insulin initiation in patients with type 2 diabetes mellitus: Treatment guidelines, clinical evidence and patterns of use of basal versus premixed insulin analogues. Eur J Endocrinol 2012;166: 159-70
14. Fritsche A, Larbig M, Owens D, et al. Comparison between a basalbolus and a premixed insulin regimen in individuals with type 2 diabetesresults of the GINGER study. Diabetes Obes Metab 2010;12:115-23
15. Testa MA, Gill J, Su M, et al. Comparative effectiveness of basalbolus versus premix analog insulin on glycemic variability and patientcentered outcomes during insulin intensification in type 1 and type 2 diabetes: A randomized, controlled, crossover trial. J Clin Endocrinol Metab 2012;97:3504-14
16. Levin PA, Zhang Q, Mersey JH, et al. Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in realworld practices: A cost-effectiveness study with a randomized pragmatic trial design. Clin Ther 2011;33:841-50
17. Korytkowski M. When oral agents fail: Practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;26:S18-24
18. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28: 2673-9
19. Ratanawongsa N, Crosson JC, Schillinger D, et al. Getting under the skin of clinical inertia in insulin initiation: The Translating Research into Action for Diabetes (TRIAD) Insulin Starts Project. Diabetes Educ 2012;38:94-100
20. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-30
21. Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009;361: 1736-47
22. American Diabetes Association. Standards of medical care in Diabetes- 2012. Diabetes Care 2012;35(suppl 1):S11-63
23. Misbin RI. The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care 2004;27:1791-3
24. ACTOS (pioglitazone hydrochloride) [full Prescribing Information]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011
25. Symlin- (pramlintide acetate) [full prescribing information]. San Diego, CA: Amylin Pharmaceuticals, Inc.; 2008
26. Victoza- (liraglutide [rDNA origin]) [full prescribing information]. Princeton, NJ: Novo Nordisk, Inc.; 2011
27. Bydureon™ (exenatide extended-release for injectable suspension) [full prescribing information]. San Diego, CA: Amylin Pharmaceuticals, Inc.; 2012
28. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: A retrospective observational pharmacy claims analysis. Diabetes Care 2010;33:2349-54
29. Byetta (exenatide) [full prescribing information]. San Diego, CA: Amylin Pharmaceuticals, Inc.; 2011
30. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, openlabel, non-inferiority study. Lancet 2008;372:1240-50
31. Invokana™ (canagliflozin) [full Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2013
32. Forxiga™ (dapagliflozin) [summary of product characteristics]. Anagni, Italy: Bristol-Myers Squibb Company; 2012
33. Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;33:2217-24
34. Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:372-82
35. Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: A randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011;13:928-38
36. Drucker DJ, Sherman SI, Gorelick FS, et al. Incretin-based therapies for the treatment of type 2 diabetes: Evaluation of the risks and benefits. Diabetes Care 2010;33:428-33
37. FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. Available at: Http://www.fda.gov/ Drugs/DrugSafety/ucm343187.htm. Accessed July 11, 2013
38. Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: A proof-ofconcept study. Diabetes Care 2010;33:1509-15
39. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-Treated patients with type 2 diabetes: A randomized, controlled trial. Ann Intern Med 2011;154:103-12
40. Vilsboll T, Rosenstock J, Yki-Jarvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:167-77
41. Barnett AH, Charbonnel B, Donovan M, et al. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin 2012;28:513-23
42. Rosenstock J, Shenouda SK, Bergenstal RM, et al. Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care 2012;35:955-8
43. Levin P, Wei W, Wang L, et al. Combination therapy with insulin glargine and exenatide: Real-world outcomes in patients with type 2 diabetes. Curr Med Res Opin 2012;28:439-46
44. Levin PA, Mersey JH, Zhou S, et al. Clinical outcomes using longterm combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus. Endocr Pract 2012;18:17-25
45. Mathieu C, Rodbard HW, Cariou B, et al. Comparison of addition of liraglutide to insulin Degludec plus metformin vs. addition of a single dose of rapid-Acting insulin analog to largest meal in type 2 diabetes. Presented at: American Diabetes Association 73rd Scientific Sessions; June 21-25, 2013; Chicago IL. Poster 911-P.